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OphthalmologyThe treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on
systemic treatment with platinum-based chemotherapy or biological compounds depending on the dis-
ease molecular proﬁle. In the last few years, intensive investigational efforts in anticancer therapy have
led to the registration of new active chemotherapeutic agents, combination regimens, and biological
drugs, expanding choices for customizing individual treatment. However, the introduction of new drugs
in the clinical setting has led to several new toxicities, creating some difﬁculties in daily management.
Among these, ocular toxicity is generally overlooked as more common toxicities such as myelosuppres-
sion, stomatitis, diarrhea, vomiting, ‘‘hand–foot syndrome’’, and neurological alterations attract greater
attention. Ophthalmic complications from cytotoxic chemotherapeutics are rare, transient, and of
mild/moderate intensity but irreversible acute disorders are possible. The best way to prevent potential
irreversible visual complications is an awareness of the potential for ocular toxicity because dose reduc-
tions or early drug cessation can prevent serious ocular complications in the majority of cases. However,
given the novelty of many therapeutic agents and the complexity of ocular pathology, oncologists may be
unfamiliar with these adverse effects of anticancer therapy. Although toxicities from chemotherapy are
generally intense but short lasting, toxicities related to targeted drugs are often milder but longer lasting
and can persist throughout treatment. Here we review the principal clinical presentations of ocular tox-
icity arising from chemotherapy [1–3], target therapies [4], and newly developed drugs and provide some
recommendations for monitoring and management of ocular toxicity.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction when the complexity of clinical status require a specialistic evalu-The treatment of non-small cell lung cancer (NSCLC) is chal-
lenging, but several new targeted agents are emerging from the
pipeline. At the same time, oncologists face the prospect of new
types of adverse events, among them ocular toxicity. Although tar-
geted agents are directed against aberrations in tumor cells, they
are associated with toxicities affecting multiple organs, including
the eye, as a result of target expression in ocular and eyelid tissue.
Ocular toxicity (Table 1) is generally underestimated and con-
sidered minor. Nevertheless, oncologists must be challenged to
recognize clinical cases and understand how to manage them; it
is also important that oncologists refer to the ophthalmologistation. Some ocular toxicity (e.g., conjunctivitis) may be diagnosed
during a normal physical examination whereas retinal damage re-
quires a specialist ophthalmologic examination.
Ocular toxicities are grouped in the CTC-AE [5] for ocular toxic-
ity, which mainly takes into account interference with the activi-
ties of daily living, as for other adverse events. However, while
for chemotherapeutics, toxicities are generally short lived and
the intensity can be considered a good marker for intervention,
toxicities for targeting agents can be long lasting albeit of relatively
mild intensity, and the existing systems for recording are not ade-
quate for measuring patient unease.
At present, with new investigational agents with known pre-
clinical ocular toxicity observed in animal models, clinical trials in-
clude specialist ophthalmologic visits; this is mandatory as part of
many study protocol procedures.
Ophthalmological toxicities arising from chemotherapy
The ocular complications associated with cancer chemothera-
peutics have been described in three major systematic reviews
Table 1
Deﬁnitions of common ocular toxicity.
Toxicity Deﬁnition
Blepharitis Inﬂammation of the eyelids, mainly at the margin; main signs are redness and ﬂaking of skin on the lids and crusting worse on waking
Central serous
retinopathy
Localized serous retinal detachment observable only on fundoscopy; manifests as slightly blurry vision and the perception of objects smaller
than they really are (micropsia)
Conjunctivitis Inﬂammation and redness of the conjunctiva
Cystoid macular
edema
Chronic inﬂammation of the macular area only observable on fundoscopy and conﬁrmed by ﬂuorescein angiography
Epiphora Excessive tear production usually caused by eye irritation
Hemianopia Visual ﬁeld defect that respects the vertical midline in both eyes; it can be homonymous or bitemporal
Keratitis Inﬂammation of the cornea, usually referring to the corneal surface (epithelium); manifests as pain, photophobia, and increased lacrimation,
more evident in slit lamp examination with the aid of a dye
Periorbital edema Inﬂammation and increased ﬂuid accumulation of the interstitial tissues from the eyelid into the orbital septum; manifests as a hard swelling
of the eyelids
Photopsia/
photophobia
Ocular pain and sensitivity to light
Trichomegaly Pathologically long eyelashes that can get misdirected and cause ocular surface abrasions
Uveitis Inﬂammation of the uveal tract; it can be anterior (involving the anterior chamber and iris) or posterior (involving the vitreous and choroid)
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we review only toxicities related to approved chemotherapeutics
for NSCLC and that are commonly used by oncologists in their daily
clinical practice, referring both to the adjuvant and to the meta-
static setting.
Cisplatin is a heavy metal compound and the cornerstone of
several antitumor therapies. All the main clinical guidelines (Amer-
ican Society of Clinical Oncology (ASCO) [6] and European Society of
Medical Oncology (ESMO) [7]) recommend a ﬁrst-line cisplatin-
based chemotherapy as the treatment of choice in the advanced
and adjuvant setting. Drugs that may be combined with platinum
include the third-generation cytotoxic drugs docetaxel, gemcita-
bine, irinotecan, paclitaxel, pemetrexed, vinorelbine and etoposide
(just for small-cell lung cancer). Neurotoxicity represents the major
dose-limiting toxicity of cisplatin. The neuropathy is uncommon
below a cumulative cisplatin dose of 400 mg/m2 but nearly univer-
sal in the cumulative-dose range of 600–800 mg/m2. The cumula-
tive dose that causes peripheral neuropathy tends to be higher in
children and younger patients than in the elderly and the risk of
neurotoxicity is higher in patients with renal dysfunction [8–10].
Visual impairment has been considered an infrequent form of cis-
platin neurotoxicity. Case reports have attributed visual alterations
to optic neuritis and cortical blindness, which have sometimes been
accompanied by seizure activity [11–14]. Ocular toxicity has gener-
ally been reported after the use of regimens with higher doses or
greater dose frequencies than those recommended by themanufac-
turer. Improvement and/or total recovery usually occurs after dis-
continuation of cisplatin [15]. An alert of possibly cisplatin-
induced retinal ischemia was reported by Kwan in 2006 [16].
Intravenous administration of carboplatin is less frequently
associated with ocular disturbances, and a few cases of maculopa-
thy, optic neuropathy, cortical blindness, sore eyes, blurred vision,
and chorioretinitis to optic neuritis have been reported [17–19]. In
any case, visual disturbances were reversible after drug cessation.
Pemetrexed is an antifolate chemotherapeutic agent. The anti-
tumor activity of this agent likely derives from inhibition of several
key folate-requiring enzymes, including thymidylate synthase,
dihydrofolate reductase, and glycinamide ribonucleotide formyl-
transferase. The drug is currently approved for the treatment of
pleural mesothelioma combined with a platinum compound and
for ﬁrst- and second-line therapy in advanced NSCLC with non-
squamous histology. The only well-known drug-related ocular ad-
verse event is conjunctivitis, also a common adverse effect of other
antimetabolite antineoplastic agents such as cytosine arabinoside,
5-ﬂuorouracil, and methotrexate [20,1,21]. This disturbance is gen-
erally associated with hyperemia, irritation, and serous secretions.
It has been reported in less than 5% of mesothelioma-naïve pa-tients who were randomly assigned to receive cisplatin in combi-
nation with pemetrexed or single-agent cisplatin, with the same
incidence in the two arms. Another case has been documented in
which a patient received pemetrexed as third-line therapy for
NSCLC advanced disease and developed conjunctivitis; this was a
cutaneous adverse event that consisted of the simultaneous occur-
rence of periorbital edema, conjunctivitis, and inﬂammatory ede-
ma of the upper and lower limbs [22].
Several prophylactic approaches have been investigated in the
prevention of antimetabolite-induced conjunctivitis. Matteucci
et al., [23] investigated in a randomized trial the efﬁcacy of dexa-
methasone in combination with diclofenac eye drops as prophy-
laxis for conjunctivitis induced by high-dose cytosine
arabinoside. They concluded that the combination of dexametha-
sone/diclofenac therapy compared with dexamethasone alone sig-
niﬁcantly prevented drug-induced conjunctivitis (incidence 13% vs.
45% respectively; p 6 0.09). Treatment of drug-induced conjuncti-
vitis usually involves the use of artiﬁcial tears, withdrawal of the
agent wich determined the toxicity, and a short course of topical
steroids, and is typically curative [1,21], even though, most of the
time, the conjunctivitis is recurrent despite symptomatic treat-
ment. Steroideal therapy (topical or systemical) should be admin-
istered only if a possible infectious has been eliminated.
Gemcitabine has structural similarities to the other antimetab-
olite chemotherapeutic drugs so that ocular toxicities cannot be
completely excluded. The drug is currently approved for the treat-
ment of advanced disease and commonly used in the locally ad-
vanced and metastatic settings. Only one case of a drug-related
visual serious adverse event has been reported,identiﬁed as a Purt-
scher retinopathy [24]. This is a rare syndrome characterized by
the appearance of a vaso-occlusive retinal injury and concomitant
presence of cutaneous vasculitis; this retinopathy was associated
with digital necrosis and antinuclear antibody elevation. Another
case report [25] of gemcitabine-induced retinopathy in a diabetic
patient presented with retinal changes that included aneurysms,
cotton-wool spots, intraretinal hemorrhages, and vascular leakage
on ﬂuorescein angiogram; clinical improvement after gemcitabine
withdrawal and relapse of retinopathy from re-exposure strongly
suggested gemcitabine to be causative of the disorder.
Docetaxel is an effective chemotherapeutic agent that is widely
used in the treatment of locally advanced and metastatic NSCLC.
Canalicular and nasolacrimal duct obstruction possibly due to stro-
mal ﬁbrosis are well-known ocular side effects of docetaxel [26].
Epiphora due to canalicular stenosis in patients treatedwithweekly
docetaxel was ﬁrst reported by Esmaeli et al., [27]. Nasolacrimal
duct obstruction secondary to treatment with docetaxel may be
partly due to stromal ﬁbrosis in the mucosal lining of the lacrimal
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preclinical observation that docetaxel is excreted via the lacrimal
glands. Early detection is important to prevent irreversible stenosis
thatwould require surgical interventionbydacryocystorhinostomy.
Skolnik and Doughman [28] also reported a case of erosive conjunc-
tivitis and punctual stenosis secondary to docetaxel administration;
the erosive conjunctivitis resolved after drug discontinuation.
Paclitaxel is as widely used as docetaxel in the treatment of lo-
cal and metastatic NSCLC. This drug is known to produce neurotox-
icity. Both transient and scintillanting scotoma and visual
impairment have been reported with paclitaxel [29]. Photopsia
usually appears during the last 30 min of the infusion and resolves
completely within 3 h. It usually occurs in patients who receive
doses of 250 mg/m2 or more but rarely can develop at doses of
175 mg/m2given intravenously [30]. One of the rare side-effects
caused by taxanes is a bilateral cystoid macular edema [31]; it
tends to be bilateral and can be conﬁrmed by its biomicroscopic
appearance on optical tomography scan, but the particularity of
this kind of ocular disorder is that it is angiographically silent; ﬂu-
orescin angiography demonstrated the unusual ﬁnding of the ab-
sence of localized retinal capillary leakage [32]. The mechanism
of this edema is not clearly understood, and existing hypotheses
do not explain this phenomenon very well. Very faint permeability
of retinal vessels has been suggested as an explanation with a
breakdown of the retinal blood-ocular barrier so minute that even
a small ﬂuorescein molecule cannot extrude or only minimally ex-
trudes. Another possible pathogenic mechanism, suggested by
Joshi and Garretson [33], is a toxic effect of paclitaxel on Müller
cells, which are responsible for maintaining osmotic gradients
within the neurosensory retina, resulting in intracellular ﬂuid
accumulation. Some patients treated with paclitaxel develop visual
evoked potential abnormalities typical of demyelinating optic neu-
ropathy; a reversible scotoma was reported by Capri et al. [29], and
the abnormal visual evoked potential suggested an involvement of
the optic nerve, comparable to the changes seen in ischemic neur-
opathies. Glaucoma also has been reported as a consequence of
paclitaxel and docetaxel therapy [34,35]. It is interesting to note
that ophthalmologists have used an in vitro model for proliferative
vitreoretinopathy to evaluate the action of paclitaxel on chorioret-
inal ﬁbroblast proliferation and contractility. Proliferative vitre-
oretinoapthy results in retinal detachment and visual impairment
due to ﬁbroblastic proliferation in the vitreous and subsequent cel-
lular contraction; dose–response curves obtained show paclitaxel
to be a potent inhibitor of both cellular events [36].
Vinorelbine is a plant alkaloid that stabilizes the microtubules
by inhibiting the polymerization of tubulin, and the drug is cur-
rently approved for the treatment of advanced NSCLC. To our
knowledge, no case of ocular toxicities has been reported with
vinorelbine.Ophthalmological toxicities arising from targeted therapies
At present, only agents targeting EGFR- and ALK-pathways have
an established role for the treatment of advanced NSCLC. However,
several targeted compounds are under investigation, and some of
them have yielded promising results in the early phases of their
development. Finally, no targeted agents have a role in the adju-
vant setting.Anti-EGFR agents
Agents targeting EGFR can be divided into at least two groups:
EGFR tyrosine kinase inhibitors (TKIs) and EGFR-targeting
monoclonal antibodies (mAbs). To date, only EGFR-TKIs and in par-
ticular geﬁtinib and erlotinib are commonly used in the clinicalpractice while afatinib and dacomitinib are now approaching this
level of use.
Geﬁtinib and erlotinib are orally active EGFR-TKIs that selec-
tively target HER1 (human epidermal growth factor receptor EGFR
[ErbB1]). In preclinical toxicity studies of geﬁtinib at 40 mg/kg/day
in rats and dogs, reversible thinning of corneal epithelium was ob-
served in both species after 1 and 6 months. Furthermore, in dogs
treated with the highest dose of geﬁtinib for 6 months, the corneal
opaciﬁcation ﬁrst observed at one month progressed on treatment
and did not reverse during a 3-monthwithdrawal period [37]. Other
EGFR inhibitors have caused similar corneal changes in preclinical
models, which are consistent with the pharmacological actions of
geﬁtinib [38]. EGFR is strongly expressed in the basal epithelial cells
of limbal and conjunctival epithelia and throughout the corneal epi-
thelium; however, little or no EGFR expression is seen in the super-
ﬁcial conjunctival or limbal epithelia, demonstrating that EGFR is
preferentially expressed in basal epithelial cells that have the great-
est proliferative potential. The EGFR ligand, EGF, promotes migra-
tion and proliferation of epithelial cells, thus facilitating corneal
epithelial wound healing. Furthermore, endogenous EGF is synthe-
tized by the lacrimal glands in response to corneal epithelial injury.
EGF occurs in high concentrations in tears and is important for nor-
mal ocular homeostasis [39]. The prescribing information for geﬁti-
nib [40] notes that eye pathologies are common and include
conjunctivitis, blepharitis,and eye dryness, events that can occur
in association with other dryness scenarios (principally cutaneous
reactions) of grade CTCAE 1 [5]. Uncommon ocular-related adverse
events include reversible corneal erosion associated with eyelash
growth. Although it appears to be a class effect associatedwith EGFR
inhibitors, the occurrence of eyelash growth in relation to EGFR
mutations is unknown; whether eyelash growth correlates with
clinical response of lung cancer to EGFR inhibitors or whether it oc-
curs as an unrelated adverse event remains to be evaluated on a lar-
ger scale. In addition, theprescribing information reports ‘‘very rare’’
cases of corneal membrane sloughing and ocular ischemia.
The prescribing information for erlotinib [41] notes that con-
junctivitis and keratoconjunctivitis sicca each occurred in 12% of
patients with NSCLC in one study [42]. Moreover, one patient in
treatment with erlotinib plus chemotherapy developed corneal
erosion/ulcer as an inﬂammatory mucous/cutaneous complication.
Bilateral periorbital rash, conjunctivitis, and eyelid ectropion have
been reported with erlotinib.
Afatinib (also called BIBW 2992) is a novel dual irreversible
EGFR/HER2 TKI that has been shown in preclinical studies to poten-
tially prevent, delay, or overcome resistance to reversible EGFR-
TKIs [43]; the preclinical in vitro and in vivo activity proﬁle includes
EGFR mutant models with activating EGFR mutations, considering
the most common mutations (L858R and deletion of exon 19) and
also the exon 20 gatekeeper T790M mutation [44,45]. The ﬁndings
from these preclinical studies prompted the investigation of afati-
nib in patients with NSCLC and EGFR mutations (LUX-Lung pro-
gram). Ocular toxicity has been reported in a few patients. In
LUX-Lung 1 trial [46], ocular effects were reported in 13% of pa-
tients who received afatinib (13% Grade 1-2, <1% Grade 3-4); simi-
lar results are reported in LUX-Lung 2 trial [47], with 20% of ocular
effects in patients received afatinib 40 mg/die and 28% in patients
received afatinib 50 mg/die, with no event of Grade 3-4 toxicity.
The two most common events were conjunctivitis and dry skin.
No data on the ocular toxicity of dacomitinib, an irreversible
EGFR-TKI pan-human inhibitor, are available [48].
Basti [49] has listed the most common ocular toxicities in pa-
tients on EGFR inhibitors:
 Squamous blepharitis: This condition typically presents with
hyperemia of the eyelid margin; it often accompanies an acne-
iform rash.
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the lashes may be misdirected inward and rub on the eyeball,
causing signiﬁcant irritation.
 Meibomitis: Patients with meibomitis complain of a burning
sensation or mild redness of the eye, often accompanied by
some mucus discharge.
 Dysfunctional tear syndrome: Dysfunctional tear syndrome can
coexist with any of the above three conditions; the tear ﬁlm is
suboptimal and causes a dry, tired sensation of the eye as well
as momentary sharp pain and/or burning.
The suggested treatment of these toxicities is mainly a warm
compress, eyelid hygiene, corticosteroids, or anti-inﬂammatory
medications. In case of keratitis or dry-eye syndrome, topical lubri-
cantsmaybeuseful. It is important tospecify that thesteroideal ther-
apy can be dangerous, should be administred on a short period of
time (10 days) and should be considered only if a possible infectious
has been eliminated. However, if important clinical manifestations
are present, dose modiﬁcation or interruption is recommended.
Table 2 lists a clinical trial sequence that is performed in lung
cancer using anti-EGFR inhibitors, with reported percentages of
ocular toxicities.
As the data in Table 2 suggest, only a few trials speciﬁed mu-
cous/cutaneous toxicities with ocular disorders. Only in the IDEAL1
trial [53] was performed an ophthalmic monitoring, which did not
reveal any signiﬁcant drug-related abnormalities or drug-related
G3 or G4 events; G1 or G2 drug-related ophthalmic adverse events
were reported in 43 patients (21%), but none required withdrawal
from therapy. Mok et al. [54] (studying efﬁcacy and safety of erloti-
nib in 1.242 East/South-east Asian patients) reported conjunctivi-
tis, blepharitis, keratitis, eye pain, dry eyes, and corneal erosion.
Ranson et al. [62] (studying geﬁtinib) reported conjunctivitis in
15.6% of patients; Baselga et al. [63] (also studying geﬁtinib) noted
that one patient had a grade 3 epithelial defect in the cornea,
caused by abnormal eyelash growth, and the patient was with-
drawn from the study. Perez-Soler et al. [64] (studying erlotinib)
noted that less than 10% of their patients exhibited signs of ocular
toxicity and that none exceeded grade 2.ALK inhibitors
The fusion oncogene, echinoderm microtubule-associated pro-
tein-like 4–anaplastic lymphoma kinase (EML4-ALK), is present
in approximately 5% of NSCLC tumors.Table 2
Clinical trials performed in lung cancer using EGFR-inhibitors and ALK-inhibitors, with re
Trial No. patients
LUX-lung 1 (afatinib) [46] 585 (33% Ca
LUX-lung 2 (afatinib) [47] 129 (87% A
TITAN (erlotinib) [50] 203 (13.8%
BR.21 (erlotinib) [42] 485 (12.9%
EURTAC (erlotinib) [51] 86 Caucasia
SATURN (erlotinib) [52] 433 Caucas
TRUST (erlotinib) [54] 1.242 Asian
IDEAL 1 (geﬁtinib) [53] 210 Asian
ISEL (geﬁtinib)[55] 1.126 Asian
INSTEP (geﬁtinib)[56] 100 (4% Asi
IPASS (geﬁtinib) [57] 607 Asian
INTEREST (geﬁtinib) [58] 729 (21.1%
First-SIGNAL (geﬁtinib) [59] 159 Asian
Northeast Japan study group: (geﬁtinib vs. Carboplatin–Paclitaxel) [60] 114 Asian
WJTOG3405(geﬁtinib) [61] 87 Asian
Phase II trial (dacomitinib vs. erlotinib) [48] 94 (24.5% A
Phase I crizotinib [66] 119 (29% A
Phase II crizotinib [67] 136 (32% ACrizotinib is an oral TKI that silences the protein product of the
ALK fusion gene and has recently been approved for the treatment
of NSCLC aberrantly expressing ALK. The efﬁcacy of crizotinib in
patients with locally advanced or metastatic ALK-positive NSCLC
has been assessed in a two-part, phase I trial and a phase II trial
[65–66]. Patients enrolled into these studies had received prior
systemic therapy, with the exception of 15 patients in the phase
II trial, who had no prior systemic treatment for locally advanced
or metastatic disease. In the phase I trial ALK-positive NSCLC was
identiﬁed using the Vysis ALK Break-Apart FISH Probe Kit; in the
phase II trial ALK-positive NSCLC was identiﬁed using a number
of local clinical trial assays. The primary efﬁcacy endpoint in both
studies was Objective Response Rate (ORR) according to Response
Evaluation Criteria in Solid Tumors (RECIST). In the phase I trial the
Objective Response Rate was 61%, with 68 patients responders
(median duration of response: 48.1 weeks); in the phase I trial
the Objective Response Rate was 61%, with 71 patients responders
(median duration of response: 48.1 weeks). In US crizotinib is ap-
proved by FDA for the treatment of patients with locally advanced
or metastatic non-small cell lung cancer (NSCLC) that is anaplastic
lymphoma kinase (ALK)-positive as detected by an FDA-approved
test; in Europe EMA has approved crizotinib not in ﬁrst-line, but
only when the disease has already been treated before. Emerging
data suggest that crizotinib may also have activity in other subsets
of lung cancer, including tumors demonstrating ampliﬁcation or
mutation of the MET oncogene, or translocation of the ROS1 onco-
gene [67]. Treatment-related visual disorders (including visual
impairment, photopsia, blurred vision, vitreous ﬂoaters, photopho-
bia and diplopia) were reported in 62% of crizotinib recipients en-
rolled in the phase I trial [65] or phase II trial [66]; most of these
events were grade 1 and usually started within 2 weeks of treat-
ment initiation.New drugs
The mitogen-activated protein kinase (MEK) pathway is a signal
transduction pathway that ultimately leads to cellular prolifera-
tion. MEK-inhibitors are a novel class of molecules under investi-
gation in multiple tumor types, including NSCLC. In particular, they
seem to be active in patients with KRAS mutations. There are many
compounds undergoing testing in clinical trials (e.g., GSK1120212,
AZD6244, PD0325901).
Visual changes observed in subjects receiving GSK1120212 may
include but are not restricted to:ported percentage of ocular toxicity.
Ocular effects
ucasian/66.1% Asian/0.9% others) 13% All grades; <1% grades 3–5
sian/12% Whit/1% Black) 28% All grades
Asian/86.2% Caucasian) N.A.
Asian/87.1% others) 9% All grades;1% grades 3–5
n N.A.
ian N.A.
14% All grades
21% All grades
N.A.
an/96% Caucasian) 5% All grades
N.A.
Asian/75.4% Caucasian/1.4% Black/2.1% others) N.A.
N.A.
N.A.
N.A.
sian/75.5% Caucasian) N.A.
sian/62% Caucasian/3% Black/6% others) 62% All grades
sian/64% Caucasian/3% Black/1% others) 62% All grades
Fig. 1. Anatomic drawing of the eye and anticancer drugs associated with ocular disorders (ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; mAbs,
monoclonal antibodies; MEK, mitogen-activated protein kinase; TKIs, tyrosine kinase inhibitors).
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 Temporarily or permanently blurred vision
 Dimness of vision
 Double vision
 Halo vision around lights
 Colorful spots or ﬂoaters
 Changes in color vision
Selumetinib (AZD6244) is an orally available, selective, non-ATP
competitive inhibitor of MEK1/MEK2 kinase; early phase clinical
studies of selumetinib monotherapy showed target inhibition
[68] and tumor response [69]; in a phase II trial selumetinib mono-
therapy showed little clinical activity in an unselected pretreated
population with NSCLC [70]. In a phase II study with selumetinib
plus docetaxel versus placebo plus docetaxel for KRAS-mutant ad-
vanced non-small-cell lung cancer [71], although the addition of
selumetinib to docetaxel as second-line treatment did not signiﬁ-
cantly improve overall survival, the combination resulted in clini-
cally meaningful and statistically signiﬁcant improvements in
progression-free survival, response and patient-reported out-
comes. Selumetinib was correlated with some ocular disorders,
such as blurred vision, diplopia, visual disturbance, eyelid edema,
increased lacrimation, subconjunctival hemorrhage, and retinal
pigment epithelium detachment.
PHA-848125 is a potent inhibitor of the kinase activity of the
CDK2/Cyclin A complex, showing activity also towards closely re-
lated CDKs (CDK1, CDK4, and CDK5) and TRKA [72,73]. The anti-
proliferative effect of PHA-848125 was tested on a panel of 120
tumoral cell lines established from different solid tumors, includ-
ing lung cancer, thymic carcinomas, leukemias and lymphomas
[74]. In combination studies, PHA-848125 exhibited synergistic
or more than additive activity when administered with docetaxel,
topotecan or temozolomide, and additive effect when combined
with bevacizumab, irinotecan, 5-FU and gemcitabine. Combina-
tions were well tolerated; ocular toxicity was observed in rats after
prolonged administration (P1 month) of PHA-848125. Bilateral
retinal atrophy occurred from the dose of 16 mg/kg/day in females
and at 24 mg/kg/day in males in the 4-week study. The sameﬁnding was seen in rats given the dose of 16 mg/kg/day for 3 cycles
of 3 weeks + 1 week rest or 5 cycles of 2 weeks + 1 week rest. This
effect did not regress after the 2- or 4-week recovery periods. The
dose of 8 mg/kg/day, given for 4 consecutive weeks or cyclically for
3 months, was the NOEL for ocular changes. No retinal changes
were seen in rats following administration of PHA-848125 for 7
consecutive days up to the highest dose (51.8 mg/kg/day).
For these patients, it is important from the beginning to have a
baseline ophthalmologic examination including visual acuity and
fundoscopy. Also useful are retinal photographs and a visual ﬁeld
examination (Fig. 1).
Conclusion
There is no consensus or recommendation about routine oph-
thalmologic monitoring and management of ocular toxicity (Ta-
ble 3). For anticancer agents that have the potential to induce
ocular adverse side effects, a baseline ophthalmologic examination
is recommended before starting treatment (e.g., visual acuity,
tonometry, fundoscopy, color vision test, automated perimetry,
retinal photographs) and during subsequent cycles of therapy.
Some ocular toxicities can be diagnosed and graded by this routine
examination whereas others (e.g., retinal detachment, altered vi-
sual acuity) require a dedicated ophthalmologic examination. In
patients who experienced peripheral neuropathy during chemo-
therapy, a particular ophthalmological evaluation including an
automated perimetry and a color vision test should be proposed
to detect an asymptomatic optic neuritis. Many side effects can
be managed just by dose interruption or dose modiﬁcation with
adequate supportive care. Anticipation of various treatment-re-
lated toxicities may provide the opportunity for clinicians to devel-
op intervention strategies that could minimize or eliminate an
expected side effect. There are many possible ways to manage ocu-
lar side effects that the patient can apply, including using a warm
compress, eyelid hygiene, corticosteroids, or anti-inﬂammatory
topical medications, or topical lubricants, and avoiding light expo-
sure (dark room, sunglasses). The use of corticosteroids, valid
therapeutical approach in many situations of ocular disorders,
Table 3
Management of common ocular toxicities (ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; mAbs, monoclonal antibodies; MEK, mitogen-activated
protein kinase; TKIs, tyrosine kinase inhibitors).
Toxicity Drug Management
Blepharitis EGFR-TKIs, EGFR mAbs Warm compress, eyelid hygiene, corticosteroids, or anti-inﬂammatory
medications
Blurred vision Cisplatin, carboplatin, paclitaxel Refer to ophthalmologist, discontinuation of cisplatin
Conjunctivitis Pemetrexed, docetaxel, oxaliplatin, EGFR-TKIs, EGFR mAbs, MEK-
inhibitors
Holding agent, corticosteroids, or anti-inﬂammatory medications,
artiﬁcial tears
Corneal edema Carboplatin Refer to ophthalmologist
Cystoid macular
edema
Paclitaxel, ALK-inhibitors Refer to ophthalmologist; holding agent
Diplopia MEK-inhibitors Refer to neurologist and ophthalmologist
Epiphora Docetaxel, ALK-inhibitors Topical lubricants, refer to ophthalmologist
Keratitis Paclitaxel Topical lubricants, refer to ophthalmologist
Lacrimal duct
stenosis
Oxaliplatin, docetaxel Holding agent, refer to ophthalmologist
Maculopathy Cisplatin, carboplatin, ALK-inhibitors, MEK-inhibitors Refer to ophthalmologist, discontinuation of cisplatin
Optic neuritis Cisplatin, carboplatin, paclitaxel ALK-inhibitors, MEK-inhibitors Refer to neurologist and ophthalmologist, discontinuation of cisplatin
Papilledema Cisplatin, oxaliplatin Corticosteroids or anti-inﬂammatory medications, discontinuation of
cisplatin
Periorbital edema Cisplatin, carboplatin, ALK-inhibitors Warm compress, refer to ophthalmologist, discontinuation of cisplatin
Periorbital rash EGFR-TKIs, EGFR mAbs Corticosteroids or anti-inﬂammatory medications, warm compress,
eyelidhygiene
Photopsia Paclitaxel Topical lubricants, avoid light exposure
Ptosis Oxaliplatin Refer to neurologist and ophthalmologist
Retinopathy Cisplatin, gemcitabine Refer to neurologist and ophthalmologist; discontinuation of cisplatin
Retinal vein
occlusion
Cisplatin, MEK-inhibitors Refer to ophthalmologist; discontinuation of cisplatin
Trichomegaly EGFR-TKIs, EGFR mAbs, MEK-inhibitors Clip long or misdirected eyelashes; refer to ophthalmologist
Uveitis MEK-inhibitors Refer to ophthalmologist
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plications. A possible choice for patients could be simply clinical
observation. However, if symptoms do not resolve or residual
symptoms are present, the patient should be promptly referred
to an ophthalmologist.
In conclusion, ophthalmic complications induced by cytotoxic
chemotherapy and target therapies are often underestimated be-
cause of the priority given to other life-threatening effects. An oph-
thalmic baseline examination prior to anticancer treatment and
careful monitoring during treatment may lead to a reduction in
ocular side effects when predisposed patients are screened and
carefully examined during administration of treatment. An annual
ophthalmologic evaluation should be proposed for patient treated
with target therapy such as EGFR-TKIs and ALK-inhibitors in order
to improve an early diagnosis of ocular disorders. All patients
should be informed about possible visual disturbance and about
the necessity of informing their oncologists as soon as they experi-
ence any ocular alteration. The possible reversal of some of these
adverse events, if discovered in time, emphasizes how important
it is for clinicians to be aware of these ocular reactions and suggest
an immediate consultation with an ophthalmologist where war-
ranted. Because of the complexity of this kind of malignancies, a
multi-disciplinary approach should be improved between different
specialists. It is very important that oncologists and ophthalmolo-
gists work together to prevent irreversible ocular toxicity and
determine the true cause of visual disturbance, as part of multi-dis-
ciplinary effort. In fact, not all visual disturbances are related to
primary ocular disorders because malignancy, metastases, or
non-oncologic diseases can also simulate some symptoms.
Finally, new toxicity criteria including not only the intensity,
but also the duration, should be introduced into the management
of patients undergoing targeted therapies.Conﬂict of interest statement
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